Products and Resources Catalog

Lack of buy-in can interfere with attempts to expand use of medication-assisted treatment (MAT) for substance use disorders. These three fact sheets offer strategies to build support for this evidence-based practice.  MAT Fact Sheet #1: Securing Buy-in            MAT Fact Sheet #2: Reducing Risk of Misuse and Diversion          MAT Fact Sheet #3: Making the Case for Medication

La falta de aceptación puede interferir con los atentos de ampliar el uso de tratamientos asistidos por medicamentos (TAM) para los trastornos por consumo de sustancias (TCS). Las Hojas Informativas de TAM ofrecen estrategias para generar apoyo para esta práctica basada en evidencia.  Hoja Informativa #1: Asegurando la Aceptación              Hoja Informativa #2: Reduciendo el Riesgo de Uso Indebido y la Desviación              Hoja Informativa #3: Abogando por las Medicamentos 

The Great Lakes ATTC, MHTTC, and PTTC have created an online flipbook for the Alcohol is STILL a Drug series. Alcohol is STILL a Drug is comprised of ten 30-minute videos recorded between September 2021–August 2022. Each video addresses the impacts of alcohol use disorder (AUD) and is presented by a leading professional in that field.    You can view the flipbook online or you can download a PDF version. The videos and supplemental resources are accessible in either format.      ABOUT THE SERIES: The opioid crisis, increasing stimulant misuse, and marijuana legalization often dominate the news—yet alcohol remains the number one substance negatively impacting physical health, mental health, social engagement, and financial stability for individuals throughout the US.   While this series will focus on the hopefulness of recovery from AUD, it will also take a deep dive into what we know about the full impact of alcohol overuse and the ways it affects everyone, even those who do not personally misuse alcohol.   The Alcohol Is Still a Drug series offers viewers the following learning objectives: Summarize the current impacts of problematic alcohol use in various/special populations, including pregnant women, youth, rural, and minority populations Assess and prioritize alcohol reduction efforts in targeted settings Describe the current efforts to curb problematic alcohol use, including best practices in providing treatment Understand the importance of person-centered approaches to treatment and recovery  

This webinar, presented by Gail D'Onofrio, MD, focused on the crucial role of the emergency department (ED) in recognizing and treating opioid use disorder (OUD) patients with evidence-based medications for addiction treatment. The opioid epidemic combined with the COVID-19 pandemic has greatly escalated the need to mitigate the morbidity and mortality associated with rising rates of fentanyl use. Dr. D'Onofrio shared data supporting the use of buprenorphine in the ED and discussed the consequences of not initiating treatment, barriers to implementation of ED buprenorphine, and components of successful integration of an ED program with community partnerships. She also shared current research by emergency physicians regarding innovative strategies like high-dose induction and use of an extended release 7-day formulation of buprenorphine. Sponsored by the Northwest and Pacific Southwest ATTCs and the Western States Node of the NIDA Clinical Trials Network. Download slides | Watch recording

The New England ATTC co-hosted the Recovery Science and Harm Reduction (RSHR) Reading Group meeting on February 24, 2022 from 12:30 PM to 1:30 PM. This discussion reviewed the article, “Patient Perspectives on Choosing Buprenorphine Over Methadone in an Urban, Equal-Access System.”  View the February 2022 RSHR Reading group meeting summary that includes a brief article summary and key themes that arose in discussion with the participants.

The Great Lakes A/MH/PTTC is offering this training for individuals working in HHS Region 5: IL, IN, MI, MN, OH, WI. This training is being provided in response to a need identified by Region 5 stakeholders.   Watch the video on YouTube     DESCRIPTION  Alcohol is STILL a drug.  The opioid crisis, increase in stimulant misuse, and marijuana legalization dominate the news— yet alcohol remains the number one substance causing health, social, legal and financial problems throughout the US.  While this series will focus on the hopefulness of recovery from alcohol use disorder, we’ll also take a deep dive into what we know about the full impact of alcohol overuse and the ways it affects every person in the US. The November 2, 2021 session will focus on the use of pharmacotherapy in the treatment of alcohol use disorders. This workshop will provide participants with information on medications used to treat alcohol use disorder. Special emphasis will be placed on medications that are utilized to treat alcohol withdrawal and those employed to support treatment and recovery.   Click "Download" above to download the infographic for this session                     At the conclusion of this workshop, participants will be able to: Identify the medications commonly used to detoxification those with alcohol use disorder Discuss the mechanism of action for disulfiram and its effect on alcohol consumption List at least two medications used to support alcohol use disorder treatment and recovery.   SPEAKER Randall Webber, MPH, CADC Randall Webber, MPH, CADC has worked in the addiction field for the past 45 years as a counselor, program director and trainer. He has provided training on street drug pharmacology, addiction science, counselor ethics and substance abuse treatment strategies. Randall has authored or co-authored numerous publications and has held teaching positions at several colleges and universities. He serves on the board of directors of the Illinois Association of Addiction Professionals.  

These Telehealth MOUD Video Demonstrations show distinct clinical interactions common across the medications for opioid use disorder (MOUD) modality. Except for the first two videos listed (Buprenorphine Induction and Re-induction to Buprenorphine), which show the same mock patient at two stages along his treatment trajectory, the videos in this collection are independent depictions showcasing different settings, patient situations, and provider types. The common thread for these videos is that each patient portrayed has an opioid use disorder and is considering or engaged in medication treatment. This set of videos may be useful for individuals entering the MOUD workforce or for MOUD patients and family members curious about what happens at various points in treatment.  Produced by the Northwest ATTC (SAMHSA grant no. TI080201), in co-sponsorship with Southeast ATTC (SAMHSA grant no. TI080215) and the ATTC Network Coordinating Office (SAMHSA grant no. TI080205). We thank the clinicians involved for their conceptual contributions to the development of these characters and the clinical scenario.

View the resources from the 2nd session of the 3-part series Embracing Pregnant & Parenting Families Challenged with Substance Use Disorder. After the session, participants will be able to: Describe evidence-based treatment for pregnant women with an opioid use disorder Recognize the impact of parent involvement in the care of newborns experiencing Neonatal Opioid Withdrawal Syndrome Develop skills and strategies to positively impact the parent-child relationship among parents with a substance use disorder   Presenter Information: Sharon Hesseltine, BSW, is President and CEO of Intentional Development, providing consultation, facilitation and training to strengthen services for pregnant and parenting families who have substance use disorders, adverse childhood experiences (ACEs) and trauma. For over 30 years Sharon has worked in Public Health and specialized in early childhood development, women’s health, substance use disorder and recovery.     Click here to watch the presentation

This is the first session of the 3-part series Embracing Pregnant & Parenting Families Challenged with Substance Use Disorder. This session addresses addiction as a chronic brain disease, the brain changes inherent to addiction and the mechanisms contributing to both the brain’s vulnerability as well as how substances themselves impact the brain.  The session strives to connect neurobiological changes to common behavior of individuals with a substance use disorder. The session also explores the overlap neurobiologically between early parenting behavior and addiction while creating an opportunity for discussion of the implications for patient care during the antepartum period After the session, participants will be able to: Recognize addiction as a chronic brain disease Understand the connection between ACE’s and vulnerability for addiction Discuss the role of the reward system in driving parenting behavior Click here to watch the video presentation Presenter Information: Sharon Hesseltine, BSW, is President and CEO of Intentional Development, providing consultation, facilitation and training to strengthen services for pregnant and parenting families who have substance use disorders, adverse childhood experiences (ACEs) and trauma. For over 30 years Sharon has worked in Public Health and specialized in early childhood development, women’s health, substance use disorder and recovery.     Continuing Education: Continuing Medical Education (CME), American Nurses Credentialing Center's Commission on  Accreditation (CNE), Certified Health Education Specialists (CHES), Iowa Credentialing Board, Missouri Board of Certification are pending approval. The series will be accepted by the Kansas Behavioral Sciences Regulatory Board and is deemed alcohol and drug specific and will be accepted for continuing education for licensed alcohol and drug counselors in Nebraska.   

BHMEDS-R3 App The BHMEDS-R3 app is designed as a quick reference for non-prescriber behavioral health professionals and consumers who need general knowledge about medications prescribed for behavioral health conditions. The language has been modified to increase readability for a larger audience and, in keeping with the goal of continuously updating the app content, new medications are added after FDA approval. Download the FREE app using the QR codes below. Use the BHMEDS-R3 app for the following: Browse through different types of behavioral health medications Click a medication category icon to learn more details, including brand and generic names Use drop-down navigation menus to learn more about medications’ purpose, dose and frequency, side effects, emergency conditions, misuse potential, and cautions. Access provider tools and other free medication resources   BHMEDS-R3 Behavioral Health Medications Originally developed as a companion piece to the Mid-America ATTC curriculum, A Collaborative Response: Addressing the Needs of Consumers with Co-Occurring Substance Use and Mental Health Disorders (2000), this publication is now available as a downloadable PDF and replicates the content included in the new BHMEDS-R3 app now available in the Apple App Store and Google Play.  Back by popular demand, this 10th Edition publication is acclaimed for its accessibility as an educational reference for addiction professionals, patients, and families. Educators and addiction counselor training programs across the United States have asked that we continue to update and publish a downloadable publication to reflect the same credible and up-to-date information included in the BHMEDS-R3 app. We attempt to update the BHMEDS-R3 app content annually and publish an updated publication biannually.    Medications are organized in 11 sections: Alcohol Use Disorder Treatment Antianxiety Medications Antidepressant Medications Antimanic/Mood Stabilizer Medications Antipsychotics/Neuroleptics Hypnotics (Sleep Aids) Medications Induced Symptoms Treatment Narcotic and Opioid Medications Opioid Use Disorder Treatment Stimulant Medications Tobacco   Each section includes the following topics for the different medication types: Generic and Brand Name Medications: includes both approved FDA approved and “off label” medications.  Purpose: Describes typical uses of medications, including specific symptoms treated and positive treatment response expected.  Dose & Frequency: Discusses when and how medications are administered.  Side Effects: Discusses potential side effects, and methods for monitoring side effects.  Emergency Conditions: Includes risks associated with overdose, withdrawal or other medications’ reactions. Misuse Potential: Elaborates upon those medications with risk factors related to misuse and/or development of physical dependence.  Cautions: Describes general guidance on risks associated with taking medications    IMPORTANT NOTES ACROSS MEDICATION TYPES Name brand medications have a limited patent. When the patent expires, the medication may be made as a generic. The generic name of a medication is the actual name of the medication and never changes. A generic medication may be made by many different manufacturers and can make several forms of a single medication with only slight variations in color, size, or shape.  

Click here to view the recording from the second ESAS session on Treatment Knowledge from 9/16/2020.

Essential Conversations in Social Services 2020 is intended for behavioral health (BH) and substance use disorder (SUD) providers in Region 7. During each episode, we will interview a subject matter expert on a timely topic and explore tips designed to help the BH and SUD workforce. During this episode we discuss Psychiatrists' View of Supporting Recovery with Dr. Melissa O'Dell from the University of Nebraska Medical Center in Omaha, NE, and Dr. Doug Burgess from Truman Medical Centers and the University of Missouri-Kansas City School of Medicine in Kansas City, MO. During this episode, our guests' share: What they are seeing in depression, anxiety, and substance use disorders.  Misconceptions about medication for depression, anxiety, and substance use disorders Advice for those who may be experiencing issues with depression, anxiety, or substance use disorders for the first time This project is brought to you by the Mid-America Addiction and Mental Health Technology transfer centers and is funded by SAMHSA, the Substance Abuse and Mental Health Services Administration. The content on this podcast does not necessarily reflect the views of SAMHSA.

This is a training on Medication Assisted Treatment

In this webinar in February 2020, Dr. Robrina Walker, University of Texas Southwestern Medical Center, described trends in the use of methamphetamine, presented about evidence-based treatments for methamphetamine use disorder, and summarized current research investigating new treatments for methamphetamine use disorder. This event was co-sponsored by the Western States Node of the NIDA Clinical Trials Network. Download slides | Watch recording

This issue of Addressing Addiction in our Native American Communities focuses on the history of the opioid crisis. 

Dr. Randy Brown will review the history of the ECHO tele-educational model and the history particular to the University of Wisconsin Project ECHO ACCEPT clinic regarding substance use disorders and related complications. He will review the general content of the curriculum and the format for these educational sessions.  Presented on November 22, 2019. 

In this webinar sponsored by the Northwest ATTC, Lydia Bartholow, DNP, PMHNP, CARN-AP investigated the connection between psychological trauma and substance use disorders, the neurobiological adaptations that arise in response to trauma, and the ways in which these same adaptations make one vulnerable to developing a substance use disorder. Viewers also learned about the relevance and importance of pharmacotherapies for treatment of substance use disorders in those with a history of trauma, and how to apply trauma-informed practices to common clinical scenarios. Download slides

The Mountain Plains ATTC partnered with University of North Dakota’s (UND) ECHO Clinic to create a seven-part ECHO series using an interdisciplinary approach to train health professionals on pain management and recovery titled, “Addressing Substance Use Disorder in 2019: An Interprofessional Approach to Pain Management and Recovery”. This seven-part ECHO Series provides a venue for a variety of health professionals to learn how to help patients/clients manage their pain without the use of opioids. Each month a different health professional presented on how to management pain from their professional perspectives (e.g., Occupational Therapist; Addiction Counselor; Nutritionist; Chiropractor; Physical Therapist; Music Therapist; and Psychiatrist) in order to promote interdisciplinary approaches especially as it relates to Opioid Use Disorders and preventing overdose. Finally, a rural perspective will be included in each session. A typical ECHO structure will be followed for the seven sessions including a 20 minute didactic followed by a case study and discussion. To view this 7-part series, other Project Echo presentations on the management of opioid use disorders (OUD), and/or get additional information visit UND’s Center for Rural Health Project Echo webpage. In addition, all Project ECHO teleECHO™ sessions are recorded and available for continuing medical education (CME) credit.

In collaboration with the New England Association of Drug Court Professionals (NEADCP) we hosted the third and final webinar of this series for individuals who wanted to learn more about MAT and its role in justice settings. This training opportunity focused on dealing with issues that a professional might encounter when handling patients with complex issues. The webinar focused on presenting a hypothetical and complex OUD court case based on factual data. The presenter explained how important life events are often not considered when conducting a comprehensive evaluation. The webinar concluded with an interactive open discussion. 

In collaboration with the New England Association of Drug Court Professionals (NEADCP) and the Opioid Response Network of New England (ORN), we created a webinar series for individuals who wanted to learn more about Medication Assisted Treatment (MAT) and its role in justice settings. The goal of this webinar was to familiarize professionals in the drug court system with opioid use disorder (OUD) as a disease and its effects. The webinar also explained how MAT works, answered the question “what is the ‘treatment’ in medication assisted treatment,” and examined why the science of OUD is important to effective treatment courts. Leading experts in the field were present to answer discussion questions.

Exploring Models for the Implementation of Medication-Assisted Treatment for Opioid Use Disorder: Knowledge and Application At state and local levels, agencies have expressed a dire need for increased access to OUD treatment to encourage individuals to enter long-term recovery. Developed by the ATTC Network CLAS Standards Workgroup, this factsheet provides concise, practical guidance to facilitate decision-making for MAT expansion. It builds on the Agency for Healthcare Research and Quality (AHRQ) technical brief titled Medication-Assisted Treatment Models of Care for Opioid Use Disorder. This AHRQ technical brief describes background and research for promising and innovative MAT models in primary care settings; it provides an overview of the models and identifies gaps in the evidence base.    

Hepatitis C virus is on the rise in rural communities of the U.S. This presentation from Judith Tsui, MD, MPH (University of Washington School of Medicine) described the syndemic of opioid use disorder (OUD) and hepatitis C (HCV). Dr. Tsui presented evidence showing the current gaps in treatment for OUD and HCV among persons who inject drugs. Based on analysis of current treatment methods and real-world patient living conditions, her presentation also described research on innovative models of care to improve treatment access and outcomes for persons with OUD and HCV. This webinar was sponsored by the Northwest ATTC and the Area Health Education Center for Western Washington (AHECWW).

Provides an overview of resources and initiatives to address opioid misuse in Indiana.  Information effective May 2019.

DESCRIPTION The purpose of the webinar is to highlight the importance of general good health and sustained employment, specifically addressing the impact of substance use and related disorders for employees, employers and workforce development programs. The webinar will: Explore the importance of general good health and substance use disorder as a public health concern Address the impact of the national opioid crisis with particular focus on DOL Region 2/HHS Region 3 Provide information about national, state and local resources available to DOL grantees and the general public about substance use disorders and treatment resources   WHO SHOULD ATTEND? This webinar is targeted to Department of Labor Region 2 (DC, DE, MD, PA, VA, WV) Employment and Training Administration Workforce Development Programs, specifically program staff working directly with participants (e.g., case managers, instructors, recruiters, administrators).   PRESENTER Renata J. Henry, MEd is the Executive Director of The Danya Institute in Silver Spring, MD. The Institute manages the Central East’s Addiction Technology Transfer Center (ATTC), Mental Health Technology Transfer Center (MHTTC) and Prevention Technology Transfer Center (PTTC), which provide training and technical assistance to the behavioral, mental health and prevention workforce in HHS Region III. Ms. Henry has more than 35 years of experience in the behavioral health field, serving in clinical and administrative positions in community-based mental health and substance abuse organizations and leadership positions in state and county government. Ms. Henry has provided leadership at a state and national level in various capacities.